Clinical trial · Interventional
Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer
Radiation Therapy With or Without Curcumin Supplement in Treating Patients With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancer is the second most incident cancer among male population worldwide. Radiation therapy by itself or along with surgery and chemotherapy are the main treatments for prostate cancer however prostate cancer cells are only modestly responsive or even unresponsive to the cytotoxic effects of radiotherapy. Recently some in vitro and in vivo studies showed radiosensitizing and radioprotective effects for curcumin. No clinical trial has been done in this area and it is not yet known whether radiation therapy is more effective with or without curcumin supplements in treating patients with prostate cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Radiation Therapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curcumin | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Curcumin Group
- description
- Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks. Patients take 3 grams of curcumin (as 6 capsules 500 mg)
- interventionNames
- Dietary Supplement: Curcumin
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks. Patients take 3 grams of placebo (as 6 capsules 500 mg)
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- Biochemical or clinical progression-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the prostate 2. Age range of 50-80 3. ECOG performance status 0-1 4. Life expectancy \> 5 years 5. Must be enrolled in a social security program 6. No other cancer, except basal cell skin cancer, that has been treated or relapsed within the past 5 years 7. No severe uncontrolled hypertension (systolic BP ≥ 160 mm Hg or diastolic BP ≥ 90 mm Hg) 8. No contraindication to luteinizing hormone-releasing hormone agonists 9. No contraindication to pelvic irradiation (e.g., scleroderma, chronic inflammatory gastrointestinal disease) 10. No hip prosthesis 11. Must not be deprived of liberty or under guardianship 12. No geographical, social, or psychological reasons that would preclude follow up Exclusion Criteria: 1. Clinical stage T3 or T4 2. Gleason score ≥ 8 3. Serum PSA ≥ 20 ng/mL and ≤ 100 ng/mL 4. other prior surgery for prostate cancer 5. concurrent participation in another clinical trial which would require approval upon entry to this trial 6. Gastrointestinal disorders such as IBD, reflux and peptic ulcers 7. Any adverse reaction to curcumin
References
Publications (0)
Data not yet available